TP53 and prostate carcinoma: In this study, our data showed that FOXD1 is capable of directly regulating the expression of G3BP2, which is capable of inhibiting p53 activity through a direct binding, which may further promote p53 nuclear export via increasing p53 sumoylation [38] and serves as a poor prognostic marker in prostate cancer patients [39].